A new study of nearly 65,000 type 2 diabetes patients found that those taking GLP-1 drugs like semaglutide were twice as likely to develop dementia or cognitive impairment over 10 years compared to non-users. But here's the twist: GLP-1 users also had significantly lower mortality. Researchers believe the drugs extend survival long enough for patients to reach the age where dementia becomes more likely. When death and cognitive impairment were combined into one outcome, there was no meaningful difference between groups. This 'survival paradox' may also explain why recent phase III trials found semaglutide did not improve cognition in Alzheimer's patients. The findings challenge earlier observational data suggesting GLP-1 drugs protect against dementia, highlighting how survival bias can distort health research conclusions.
